Blueprint gains approval for its first drug, a treatment for a rare gastrointestinal cancer
- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
Blueprint Medicines won approval Thursday of its first drug, a precision medicine that dramatically shrank tumors caused by an ultra-rare form of gastrointestinal cancer. The Food and Drug
Administration’s approval of the medicine for a form of gastrointestinal stromal tumors, or GIST, marks an “incredibly exciting milestone for our company and, more importantly, for GIST
patients,” said Jeff Albers, chief executive officer of the biotech based in Cambridge, Mass. The FDA action was widely expected, and Blueprint shares closed up less than 1 percent. STAT+
Exclusive Story Already have an account? Log in THIS ARTICLE IS EXCLUSIVE TO STAT+ SUBSCRIBERS UNLOCK THIS ARTICLE — PLUS DAILY COVERAGE AND ANALYSIS OF THE BIOTECH SECTOR — BY SUBSCRIBING
TO STAT+. Already have an account? Log in Individual plans Group plans View All Plans To read the rest of this story subscribe to STAT+. Subscribe